دورية أكاديمية
Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients ( ex-vivo study).
| العنوان: | Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients ( ex-vivo study). |
|---|---|
| المؤلفون: | El-Houseini ME; Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Arafat MS; Biotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt., El-Husseiny AM; Zoology department, Faculty of Science, Cairo University, Giza, 12613, Egypt., Kasem IM; Biotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt., Kamel MM; Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., El-Habashy AH; Department of Pathology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Khafagy MM; Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Radwan EM; Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Helal MH; Radio-Diagnosis Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt., Abdellateif MS; Medical Biochemistry and Molecular Biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt. |
| المصدر: | Oncology research [Oncol Res] 2022 Oct 10; Vol. 29 (5), pp. 319-330. Date of Electronic Publication: 2022 Oct 10 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Tech Science Press Country of Publication: United States NLM ID: 9208097 Publication Model: eCollection Cited Medium: Internet ISSN: 1555-3906 (Electronic) Linking ISSN: 09650407 NLM ISO Abbreviation: Oncol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Henderson, NV : Tech Science Press Original Publication: New York : Pergamon Press, c1992- |
| مواضيع طبية MeSH: | Vascular Endothelial Growth Factor A* , Neoplasms*, Humans ; Animals ; Female ; Immunotherapy ; Coculture Techniques ; Down-Regulation ; Forkhead Transcription Factors |
| مستخلص: | Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs ( p = 0.001 and 0.017, respectively), similarly upregulation of CD8, CD4 and CD103 on T cells ( p = 0.031, 0.027, and 0.011, respectively). While there was a significant downregulation of FOXP3 and combined CD25.CD8 expression on regulatory T cells ( p = 0.014 for both). Increased CD8/Foxp3 ratio ( p < 0.001) was also observed. CD133, CD34 and CD44 were downregulated on BCCs ( p = 0.01, 0.021, and 0.015, respectively). There was a significant increase in interferon-γ (IFN-γ, p < 0.001), lactate dehydrogenase (LDH, p = 0.02), and a significant decrease in vascular endothelial growth factor (VEGF, p < 0.001) protein levels. Gene expression of FOXP3 and Programmed cell death ligand 1 (PDL-1) were downregulated in BCCs ( p < 0.001, for both), similarly cytotoxic T lymphocyte antigen-4 (CTLA4, p = 0.02), Programmed cell death 1 (PD-1, p < 0.001) and FOXP3 ( p < 0.001) were significantly downregulated in T cells. Conclusion: Ex-vivo activation of immune cells (DCs, T cells, TIDCs, and TILs) with immune checkpoint inhibitors could produce a potent and effective BC immunotherapy. However, these data should be validated on an experimental animal model to be transferred to the clinical setting. Competing Interests: The authors declare that they have no conflicts of interest to report regarding the present study. (© 2022 El-Houseini et al.) |
| References: | Oncotarget. 2017 Feb 21;8(8):13703-13715. (PMID: 28099147) JCI Insight. 2019 Oct 3;4(19):. (PMID: 31465302) J Clin Oncol. 2013 Sep 1;31(25):3083-90. (PMID: 23897954) J Egypt Natl Canc Inst. 2008 Dec;20(4):379-86. (PMID: 20571596) Oncol Lett. 2018 Jul;16(1):529-535. (PMID: 29928442) Immunology. 2006 Jun;118(2):240-9. (PMID: 16771859) Nat Rev Immunol. 2004 Dec;4(12):941-52. (PMID: 15573129) Life Sci. 2020 Apr 15;247:117437. (PMID: 32070710) Int J Environ Res Public Health. 2017 Jan 12;14(1):. (PMID: 28085094) Clin Dev Immunol. 2011;2011:430394. (PMID: 22110524) J Oncol. 2019 Sep 16;2019:7512632. (PMID: 31636668) Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54. (PMID: 17671115) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Sci Transl Med. 2016 Mar 2;8(328):328rv4. (PMID: 26936508) Histopathology. 2020 Oct;77(4):560-569. (PMID: 32333690) Nat Rev Immunol. 2012 Mar 22;12(4):253-68. (PMID: 22437938) Acta Histochem. 2014 Jan;116(1):148-57. (PMID: 23899963) Oncotarget. 2015 Oct 20;6(32):33972-81. (PMID: 26378017) PLoS One. 2013 Oct 04;8(10):e76379. (PMID: 24124553) Breast Cancer Res. 2015 Sep 04;17:124. (PMID: 26341640) Cancer Res. 2007 Jun 1;67(11):5479-88. (PMID: 17545630) Cancer J. 2014 Jul-Aug;20(4):256-61. (PMID: 25098285) Ann Oncol. 2014 Aug;25(8):1536-43. (PMID: 24915873) J BUON. 2018 Mar-Apr;23(2):372-377. (PMID: 29745079) Nat Immunol. 2003 Apr;4(4):330-6. (PMID: 12612578) Breast Care (Basel). 2018 Mar;13(1):22-26. (PMID: 29950963) Adv Pharm Bull. 2015 Jun;5(2):261-7. (PMID: 26236666) Mol Immunol. 2009 Jan;46(3):457-72. (PMID: 19081138) PLoS One. 2013 Dec 23;8(12):e83710. (PMID: 24376736) Curr Cancer Drug Targets. 2010 Nov;10(7):728-36. (PMID: 20578982) Blood. 2018 Jan 4;131(1):58-67. (PMID: 29118008) Clin Cancer Res. 2019 May 1;25(9):2725-2736. (PMID: 30635338) Mol Ther. 2018 Jan 3;26(1):45-55. (PMID: 29258739) Mol Med Rep. 2016 Jun;13(6):5193-9. (PMID: 27121210) JCI Insight. 2017 Dec 7;2(23):. (PMID: 29212947) Oncotarget. 2015 Jul 10;6(19):17462-78. (PMID: 25968569) Exp Ther Med. 2021 Sep;22(3):958. (PMID: 34335900) Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870) Clin Cancer Res. 2016 Dec 15;22(24):6290-6297. (PMID: 27267849) Mol Cancer. 2017 Jul 17;16(1):124. (PMID: 28716029) J Clin Invest. 2015 Sep;125(9):3627-41. (PMID: 26301814) Expert Rev Anticancer Ther. 2012 Dec;12(12):1597-611. (PMID: 23253225) J Exp Med. 2013 Jul 1;210(7):1389-402. (PMID: 23752227) J Transl Med. 2013 Jan 15;11:16. (PMID: 23320561) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Immunopharmacol Immunotoxicol. 2020 Aug;42(4):346-357. (PMID: 32515626) |
| فهرسة مساهمة: | Keywords: CTLA4; Immunotherapy; PD1; TIDCs; TILs; breast cancer |
| المشرفين على المادة: | 0 (Vascular Endothelial Growth Factor A) 0 (Forkhead Transcription Factors) |
| تواريخ الأحداث: | Date Created: 20230612 Date Completed: 20230613 Latest Revision: 20231102 |
| رمز التحديث: | 20231102 |
| مُعرف محوري في PubMed: | PMC10207991 |
| DOI: | 10.32604/or.2022.025249 |
| PMID: | 37305162 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!